Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MORPHIC HOLDING, INC.

(MORF)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Morphic Holding, Inc. Appoints Nisha Nanda to the Board of Directors

08/23/2021 | 05:04pm EST

Morphic Therapeutic announced the appointment of Nisha Nanda, Ph.D., to its Board of Directors. Dr. Nanda currently serves as the chief development officer for Loxo Oncology at Lilly. Dr. Nanda has two decades of experience in the biopharma industry, holding various roles of responsibility in both clinical and pre-clinical development. Prior to Loxo Oncology, Dr. Nanda worked on the clinical development of carfilzomib (Kyprolis) and the approval of omacetaxine (Synribo). Her career in drug development has included roles at Onyx, ChemGenex, Portola, Millennium and COR.


ę S&P Capital IQ 2021
All news about MORPHIC HOLDING, INC.
11/16Morphic presents preclinical data from v 8 integrin program at the sitc annual meeting
AQ
11/16Morphic Announces Participation in Upcoming Investor Conferences
AQ
11/15Morphic Presents Preclinical Data from αvβ8 Integrin Program at the SITC Ann..
GL
11/15Morphic Holding, Inc. Presents Preclinical Data from Av?8 Integrin Program at the SITC ..
CI
11/15MORPHIC : November 2021 SITC AVB8 Presentation
PU
11/04Morphic Announces Corporate Highlights and Third Quarter 2021 Financial Results - Form ..
PU
11/04MORPHIC HOLDING, INC. Management's Discussion and Analysis of Financial Condition and ..
AQ
11/04Morphic Holding, Inc. Reports Earnings Results for the Third Quarter and Nine Months En..
CI
11/04MORPHIC HOLDING, INC. : Results of Operations and Financial Condition, Change in Directors..
AQ
11/04Morphic Holding, Inc. Announces the Resignation of Peter G. Linde as Chief Medical Offi..
CI
More news
Analyst Recommendations on MORPHIC HOLDING, INC.
More recommendations
Financials (USD)
Sales 2021 25,0 M - -
Net income 2021 -89,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -17,7x
Yield 2021 -
Capitalization 1 634 M 1 634 M -
Capi. / Sales 2021 65,4x
Capi. / Sales 2022 65,4x
Nbr of Employees 101
Free-Float 67,4%
Chart MORPHIC HOLDING, INC.
Duration : Period :
Morphic Holding, Inc. Technical Analysis Chart | MORF | US61775R1059 | MarketScreener
Technical analysis trends MORPHIC HOLDING, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 44,21 $
Average target price 100,50 $
Spread / Average Target 127%
EPS Revisions
Managers and Directors
Praveen P. Tipirneni President, Chief Executive Officer & Director
Marc Schegerin Chief Operating & Financial Officer
Gustav A. Christensen Chairman
Bruce N. Rogers Chief Scientific Officer
Peter G. Linde Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MORPHIC HOLDING, INC.34.75%1 634
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641